Speaker illustration

Doctor Derk Pol

Monash Heart, Melbourne (Australia)

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

Event: ESC Congress 2020

Topic: Pharmacotherapy

Session: Acute Coronary Syndromes ePosters

Thumbnail

2-year real-world outcomes of prasugrel, ticagrelor or clopidogrel therapy following percutaneous coronary intervention from a large multi-centre Australian registry.

Event: ESC Asia with APSC & AFC 2020

Topic: Pharmacotherapy

Session: Abstract Programme

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb